DMN:FRA
Diamyd Medical AB
0,063 €
arrow_downward
-0,63%(-0,00040) 1 d.
13. 11., 22:00:00 GMT+1 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre DMN…
Otvoriť
0,06 €
Vysoká
0,06 €
Nízka
0,06 €
Trh. kap.
139,51 mil.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
1,80 €
Min. za 52 týž.
0,05 €
Počet zamestnancov
42
Otvoriť
0,06 €
Vysoká
0,06 €
Nízka
0,06 €
Trh. kap.
139,51 mil.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
1,80 €
Min. za 52 týž.
0,05 €
Počet zamestnancov
42
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
TradingKey
·
pred 4 hodinami
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
Foreign Policy Journal
·
pred 4 hodinami
Dow Jones Industrial Average (DJIA) Stays Green While Nasdaq Tumbles Nearly 1% In Sharp Rotation Trade
TradingView
·
pred 11 hodinami
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
pred 11 hodinami
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profil
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Informácie o subjekte Diamyd Medical AB
Generálny riaditeľUlf Hannelius
Zamestnanci42
Dátum založenia1984
Hlavné sídlo-
OdvetvieHealth Care
Odvetvie-
Webdiamyd.com